Abstract: The present invention relates to the field of immunogenic compositions and the use of such compositions in medicine. More particularly, it relates to immunogenic compositions comprising an immunogenic polypeptide from non-typeable Haemophilus influenzae, a PE-PilA fusion protein, and optionally an immunogenic polypeptide of UspA2 from Moraxella catarrhalis, for use in subjects having chronic obstructive pulmonary disease (COPD), in particular for reducing the frequency of severe exacerbations (i.e. severe AECOPDs).

Abstract: The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1? and TNF-? cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.

Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.

Abstract: The present invention relates to the field of antigen binding proteins and the use of such antigen binding proteins in an assay. More particularly, it relates to antigen binding proteins which bind to an epitope of Protein E and antigen binding proteins which bind to an epitope of PilA. The present invention also relates to assays (particularly in vitro assays) for assessing binding to Protein E and/or PilA and the potency of vaccines containing Protein E and/or PilA. In particular the invention relates to in vitro relative potency assays used in the release of a vaccine to the public.